## Abstract We sought to review the long‐term tolerability of tetrabenazine (TBZ) and seek determinants of tolerability in the treatment of hyperkinetic movement disorders. A retrospective chart review was performed on patients treated with TBZ between 1997 and 2004. Efficacy of TBZ was assessed by
Tetrabenazine therapy of pediatric hyperkinetic movement disorders
✍ Scribed by Samay Jain; Paul E. Greene; Steven J. Frucht
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 78 KB
- Volume
- 21
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
Tetrabenazine (TBZ), a presynaptic dopamine depletor and postsynaptic dopamine receptor blocker, is widely used for the treatment of hyperkinetic movement disorders in adults. However, reports of its use in children are limited. We review the efficacy and tolerability of TBZ therapy in 31 children with hyperkinetic movement disorders refractory to other medications. TBZ was effective in reducing the severity of movement disorders resistant to treatment with other medicines. When compared to adult patients, pediatric patients required higher doses. Side effects were similar to the adult population; however, children had a lower incidence of drug‐induced Parkinsonism. © 2006 Movement Disorder Society
📜 SIMILAR VOLUMES
We report three members of a single family who developed a newly described combination of myoclonus and chorea in association with mild ataxia. The occurrence of this and related syndromes suggests that inherited, slowly progressive myoclonus, chorea, and dystonia, alone or in combination, should be
## Abstract The role of the basal ganglia in conditions with co‐occurring movement disorders and neuropsychiatric symptoms is not well known. It has been hypothesized that hyperkinesia ‐disinhibited behaviors and hypokinesia‐inhibited behaviors result from an imbalance between the direct and indire